FORMULATION, DEVELOPMENT AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLET OF METHIMAZOLE

Sustained release tablets are generally taken once or twice a day during a course of treatment whereas in conventional dosage forms there is need to take 3-4 times dosage in a day to achieve the same therapeutic action. The drug was confirmed using FTIR, DSC and UV Spectroscopy, and tested for the stability of drug and polymer interactions. The tablet is formulated using carbopol, Ethyl cellulose and Eudragit, which makes it a matrix tablet, the carbopol is hydrophilic in nature and ramming two are hydrophobic in nature, which controls the release of drug. This formulation was tested for Mucoadhession, Swelling, erosion, adhesion retention, Pre compression and post compression parameters, tested for in vitro drug release as dissolution and tested for stability.